Core Viewpoint - 康龙化成 has signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong to issue 58,440,762 new H-shares at a price of HKD 22.82 per share, aiming to raise approximately HKD 1,333.6 million [1][2] Group 1 - The placement shares represent approximately 19.86% of the existing issued H-shares and 3.30% of the total issued shares as of the announcement date [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1,318.7 million, with a net price per share of approximately HKD 22.56 [2] - The company plans to allocate about 70% of the net proceeds for project construction to enhance laboratory service facilities and production capacity [2] Group 2 - Approximately 10% of the proceeds will be used to repay bank loans and other borrowings to optimize the company's capital structure [2] - About 20% of the funds will be allocated to supplement working capital and other general corporate purposes [2] - The board believes that this issuance will strengthen the company's financial position, capture industry opportunities, and support capacity investment and business expansion [2]

Core Viewpoint - 康龙化成 has signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong to issue 58,440,762 new H-shares at a price of HKD 22.82 per share, aiming to strengthen its capital structure and support business expansion [1][2] Group 1: Placement Details - The number of placement shares represents approximately 19.86% of the existing issued H-shares and 3.30% of the total issued shares as of the announcement date [1] - If fully subscribed, the total proceeds from the placement are expected to be approximately HKD 1,333.6 million, with a net amount of about HKD 1,318.7 million [2] - The net price per placement share is approximately HKD 22.56 [2] Group 2: Use of Proceeds - Approximately 70% of the net proceeds will be used for project construction to enhance laboratory service facilities, drug process development, and production capacity [2] - About 10% will be allocated to repay bank loans and other borrowings to optimize the company's capital structure [2] - Approximately 20% will be used to supplement working capital and for other general corporate purposes [2] Group 3: Strategic Implications - The board believes that the company is a leading integrated pharmaceutical R&D and manufacturing service platform, committed to strengthening service capabilities and accelerating global drug innovation [2] - The issuance is expected to enhance the company's financial strength, capture industry opportunities, and support capacity investment and business expansion [2] - The placement will introduce high-quality international institutional investors, expand the shareholder base, and significantly enhance the liquidity of H-shares [2]